What Is GLP-3? Exploring the Research Behind a Triple GLP-1, GIP, and Glucagon Receptor Agonist

GLP-3 is among the most intriguing experimental peptides in modern metabolic research. It has attracted significant attention because it is not a traditional GLP-1 analogue but rather a triple receptor agonist, acting simultaneously on the GLP-1, GIP, and glucagon receptors. This unique combination distinguishes it from peptides that target only one or two metabolic pathways.

In the scientific literature, GLP-3 is primarily being investigated for its potential role in body weight regulation, glucose metabolism, energy expenditure, and metabolic disorders associated with obesity. Clinical studies have identified it as a highly promising candidate in the field of metabolic medicine. However, it is important to emphasize that GLP-3 remains an investigational compound, and its long-term profile continues to be evaluated.

Why Is GLP-3 Unique?

Most well-known metabolic peptides primarily target the GLP-1 receptor, which is associated with reduced appetite, slower gastric emptying, and improved glycemic control. GLP-3 goes a step further.

Research suggests that its effects are based on the simultaneous activation of three receptor systems:

• GLP-1 receptor – associated with appetite regulation, insulin response, and postprandial glucose control.
• GIP receptor – involved in insulin signaling and nutrient metabolism.
• Glucagon receptor – linked to increased energy expenditure and enhanced fat oxidation.

The combination of these mechanisms is why GLP-3 is frequently described in the scientific literature as one of the most comprehensive molecules currently being investigated for metabolic regulation.

How Does GLP-3 Work According to Current Research?

1. Appetite Regulation and Energy Intake

One of the most closely studied areas of GLP-3 research is its effect on appetite and caloric intake. Activation of the GLP-1 pathway has been associated with increased satiety and reduced spontaneous food consumption.

Clinical studies have shown that participants with obesity experienced significant changes in body weight during treatment periods, suggesting that GLP-3 may influence the central regulation of hunger and satiety.

2. Increased Energy Expenditure

One feature that differentiates GLP-3 from many other metabolic peptides is its activation of the glucagon receptor. Research has linked this mechanism to increased energy turnover, enhanced fat oxidation, and changes in basal metabolic activity.

In other words, the observed effects may not be solely related to reduced caloric intake but also to how the body utilizes and expends energy.

3. Metabolic Parameters and Glucose Homeostasis

Clinical data have also demonstrated that GLP-3 may influence several additional metabolic markers, including:

• Fasting blood glucose levels
• Insulin sensitivity
• Triglyceride concentrations
• Certain indicators of liver fat accumulation

These findings explain why GLP-3 is being investigated not only in obesity research but also in studies involving metabolic syndrome, insulin resistance, and lipid metabolism disorders.

What Have Clinical Studies Shown?

GLP-3 gained widespread attention following the publication of data from a Phase 2 clinical trial evaluating its effects in adults with obesity or overweight.

The results demonstrated that higher doses produced substantial reductions in body weight over a 48-week period, among the most significant outcomes reported for metabolic peptides studied to date.

Researchers also monitored several additional markers related to metabolic health, including:

• Waist circumference
• Blood pressure
• Lipid profile
• Measures of glycemic control

These findings are a key reason why GLP-3 is often referred to in scientific publications as one of the most promising next-generation candidates in metabolic research.

GLP-3 vs. GLP-1 Peptides: What Is the Difference?

GLP-3 is frequently compared with molecules such as Retatrutide, Semaglutide, and Tirzepatide, but its mechanism of action is broader.

While:

• Semaglutide primarily targets the GLP-1 receptor,
• Tirzepatide combines GLP-1 and GIP receptor activity,
• GLP-3 adds glucagon receptor activation, influencing not only appetite and insulin signaling but also energy expenditure and lipid metabolism.

For this reason, scientific publications often suggest that GLP-3 may represent the next evolutionary step in peptide-based metabolic research.

What Is Currently Being Investigated?

Although the findings to date are highly encouraging, GLP-3 research is still ongoing. Current areas of investigation include:

• Long-term safety
• Tolerability at higher doses
• Sustainability of metabolic changes over time
• Effects on liver fat accumulation and cardiometabolic markers
• Comparisons with other modern receptor agonists

An important component of ongoing research is the evaluation of gastrointestinal tolerability. Similar to other incretin-based peptides, the most commonly reported effects in studies have included nausea, vomiting, diarrhea, and delayed gastric emptying, particularly during dose-escalation phases.

Conclusion

GLP-3 is one of the most widely discussed experimental peptides in contemporary metabolic research. Scientists view it as a highly promising molecule for the study of body weight regulation, energy metabolism, and glucose homeostasis.

What sets GLP-3 apart from many other investigational compounds is its triple receptor mechanism, which simultaneously targets several key metabolic pathways. Current clinical data demonstrate a powerful biological effect, although it remains an experimental molecule whose long-term profile continues to be assessed.

For the scientific community, GLP-3 represents an important model for understanding what the next generation of metabolically active peptides may look like.

References

• Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.New England Journal of Medicine.DOI: 10.1056/NEJMoa2301972

• Eli Lilly and Company. Clinical Development Data for Retatrutide (LY3437943).

• Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The New Biology and Pharmacology of Glucagon.Physiological Reviews.

• Finan B, Yang B, Ottaway N, et al. A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents.Nature Medicine.

• Frias JP, Nauck MA, Van J, et al. Research on GLP-1/GIP multi-agonists and metabolic peptides as a comparative foundation for modern metabolic therapeutics.